Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Martin Whitman’s Third Avenue Management Reduced Its Position in $CTL.TO

Martin Whitman’s Third Avenue Management filed 13D on October 27th for its 30.4% activist stake in Catalyst Paper Corporation (CTL.TO). According to the filing, Third Avenue Management has sold 7.56 million shares in total since June 3rd this year as the share price dropped all the way down. Third Avenue Management was Catalyst Paper Corporation’s large stakeholder since late 2006, when it took approximately 38% of the company’s stock.  The firm now still remains about 116 million shares in its position. CTL.TO has lost about 70% year to date. It’s now trading below its price level in the financial crisis.

Third Avenue Management is managed under Martin Whitman. He is an American investment advisor who once made some critic changes in GAAP. He is founder, Co-Chief Investment Officer, and Portfolio Manager of the Third Avenue Management. Based on the firm’s latest 13F, it had $4.9 billion portfolio value in the second quarter, and mainly invested in Financial, Basic Material, and Technology sector.

According to the company’s official website, Catalyst Paper Corp manufactures diverse specialty printing papers, newsprint and pulp. The company sells its products to retailers, publishers and commercial printers in North America, Latin America, the Pacific Rim and Europe. Catalyst has a combined annual production capacity of 1.9 million tonnes.  The company is headquartered in Richmond, British Columbia, Canada and its common shares trade on the Toronto Stock Exchange under the symbol CTL.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!